Labcorp Venture Fund Research
Investment Thesis
Labcorp Venture Fund is the corporate venture arm of Labcorp, the diagnostics and drug development company. It invests in startups across the healthcare continuum that make care more personalized, convenient, accessible and data-driven. The fund has invested since 2012 and says it has made 85+ direct investments, has 50+ active investments, and has deployed $300M+. About 60% of portfolio companies work with Labcorp beyond the investment.
Focus Areas
The fund lists these investment areas:
- Diagnostic innovations, including new tests, platforms and services
- Novel biomarkers
- Precision medicine
- Early development and cell and gene therapy services
- Consumer wellness, convenience and engagement
- Digital health and technology
- Real-world evidence
- Point of care solutions
- Logistics, operations and automation
- Clinical trial recruitment, decentralization and optimization
- Data aggregation and exchange
- Population health, bioinformatics and value-based care
- Clinical decision support and patient care management
Stage Focus
Labcorp describes the fund as investing in early-stage private companies in current or strategically adjacent spaces. Its recent public rounds skew later: Series B rounds for Nanopath (November 2026), Evvy (September 2026) and Precede Biosciences (January 2026). Labcorp Venture Fund does not publish a stage rule or a check size.
Lead Tendency
In the public rounds found since late 2025, Labcorp Venture Fund took part without leading. Founders should expect to bring a lead investor, and should ask early how much the fund invests.
What Labcorp Adds
Founders get access to Labcorp's scientific, technical and commercial expertise, its touchpoints across the healthcare system, its healthcare data, analytics and technology assets, and its work in clinical care and drug development. Collaborations with portfolio companies have included a lab-ordering collaboration with Praia Health announced in November 2024.
Recent Activity
- Nanopath: Series B, November 2026, point-of-care molecular diagnostics for women's health
- Evvy: Series B, September 2026, vaginal microbiome testing
- Precede Biosciences: Series B, January 2026, blood-based precision diagnostics
- SiteLabs: seed round, October 2025, preventive care and research through independent pharmacies
- Prenosis: investment described by Labcorp in September 2025, AI for sepsis
- Praia Health: strategic investment, November 2024
Portfolio Highlights
The portfolio page lists about 50 companies, including Evvy, Teal Health, Prenosis, Precede Biosciences, Emulate, HealthVerity, Geneoscopy, Cofactor Genomics, Next Gen Jane, Oova, Imvaria, IgniteData, Olaris, Artisight, Praia Health and SiteLabs. The mix is diagnostics, women's health, health data, clinical trial tools and care delivery software. The fund also has a page of exited companies.
Team
- Megann Vaughn Watters: Vice President and Head of Labcorp Venture Fund, within Labcorp's New Ventures and Strategic Alliances group. Began as a lab-bench scientist in biomedical engineering.
- Vikki Walsh: Director, New Ventures and Strategic Alliances at Labcorp.
The Labcorp venture team includes former bankers, scientists and physicians.
Decision Process
Investment decisions run through Labcorp's corporate development and new ventures group. The fund does not publish a timeline or a pitch channel. A warm introduction through a portfolio founder or a co-investor is the practical route.
Founder Preferences
The fund favors companies where Labcorp's labs, data or clinical network can help: new tests and platforms, biomarkers, trial recruitment and operations. Companies with no tie to diagnostics, clinical research or care delivery are a weaker fit.
Geographic Focus
The fund is based in Burlington, North Carolina. Most known portfolio companies are in the United States, with a few in Europe such as Vitestro in the Netherlands and Biospectal in Switzerland.